Document text
Principal Investigator: Robert P. Kimberly
Organization: UNIVERSITY OF ALABAMA AT BIRMINGHAM
Fiscal Year: 2021
Award: $807,056
Funding agency: National Center for Advancing Translational Sciences
ABSTRACT
The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating impact on the health
of communities, clinically, socially and economically. Preventive approaches require an understanding of the
virus prevalence and the level of herd immunity in the general population. As part of a previous natural history
study, the Center for Clinical and Translational Science (CCTS; University of Alabama at Birmingham [UAB])
collaborated with the University of Pittsburgh Clinical and Translational Science Institute (CTSI) and the
National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Disease (LID) to
coordinate a national COVID-19 seroprevalence project. This study established a near-representative, nation-
wide cohort of 11,300 participants who had not been diagnosed with the virus to provide biospecimens to
evaluate baseline immunity across the United States. To examine the time-dependent population prevalence of
detectable antibodies to SARS-COV-2, this scientific partnership of academic medical centers and the NIH’s
intramural research program will recall and re-consent the established cohort to submit additional blood
specimens and clinical information at 6- and 12-month time points from their original enrollment date to
understand changes in COVID-19 immunity across the country (Aim 1). Newly obtained biospecimens will be
used to determine the immune attributes associated with health outcomes, including outcomes in special or
underrepresented populations and individuals across the life course (Aim 2). This work benefits from the deep
expertise in the basic and applied research of infectious diseases as well as viral vaccine development, host
immune response to viruses, and viral molecular biology and genetics at the National Institute for Allergy and
Infectious Diseases (NIAID). It also leverages the rigorous and efficient capacity maintained by Clinical and
Translational Science Awards (CTSA) Hubs at UAB and Pittsburgh to rapidly engage diverse cohorts of
participants nationally to accelerate translational research that is high priority scientifically and for eventual
public health practice. From this study, the collaborative team will gain crucial insights into the longitudinal
impact of the COVID-19 pandemic across the country and will identify potential targets for a vaccine. These
data are essential to assess the impact of public health efforts and to guide ongoing COVID-19 response.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><21+ years old><Academic Medical Centers><Adult><Adult Human><Alabama><Antibodies><Antibody titer measurement><Applied Research><Applied Science><Assay><Basic Research><Basic Science><Bioassay><Biologic Assays><Biological Assay><Biological Markers><Blood Sample><Blood Serum><Blood specimen><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 antibody><COVID-19 crisis><COVID-19 diagnosis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immunity><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 virus><COVID19><COVID19 crisis><COVID19 diagnosis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 immunity><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 virus><CV-19><CV19><Clinical><Clinical Sciences><Clinical and Translational Science Awards><CoV-2><CoV2><Communicable Diseases><Community Health><Consent><Country><DNA Molecular Biology><Data><Development><Diagnosis><Disease Outbreaks><Economics><Enrollment><Future><General Population><General Public><Goals><Health><Herd Immunity><Humoral Immunities><Immune><Immune response><Immunes><Immunity><Immunological response><Incidence><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Institutes><Intramural Program><Intramural Research Program><Knowledge><Life Cycle><Life Cycle Stages><Molecular Biology><Molecular Genetics><Morbidity><Morbidity - disease rate><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Natural History><Outbreaks><Outcome><Participant><Phase><Population><Prevalence><Preventive><Public Health><Public Health Practice><Role><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 diagnosis><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immunity><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Seroprevalences><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Special Population><Testing><Time><Translational Research><Translational Science><Underrepresented Groups><Underrepresented Populations><United States><United States National Institutes of Health><Universities><University Medical Centers><Vaccines><Viral><Viral Vaccines><Virus><Work><Wuhan coronavirus><adulthood><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody based detection><antibody based test><antibody detection><antibody test><antibody titering><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antibody-based immunity><bio-markers><biologic marker><biomarker><clinical center><cohort><community-based health><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 diagnosis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immunity><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><detect antibodies><develop a vaccine><development of a vaccine><developmental><diagnosed with COVID-19><diagnosed with COVID19><diagnosed with SARS-CoV-2><diagnosed with coronavirus 2019><diagnosed with coronavirus disease 2019><eligible participant><enroll><hCoV19><host response><immune system response><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunological status><immunoresponse><insight><life course><mortality><nCoV2><novel><pandemic><pandemic disease><pathogen><phase 2 study><phase II study><response><screening><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 diagnosis><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><social><social role><translation research><under representation of groups><under represented groups><under represented populations><underrepresentation of groups><vaccine development><vaccine formulation>